Effect of Treatment on Health-Related Quality of Life in Acquired Immunodeficiency Syndrome (AIDS)-Related Kaposi's Sarcoma: A Randomized Trial of Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine

Abstract

The purpose of this study was to determine whether health-related quality of life (HRQL) would be improved in patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma treated by pegylated-liposomal doxorubicin (PLD) as compared to those treated by a conventional combination of doxorubicin, bleomycin, and vincristine (ABV). One hundred thirty-three patients received PLD and 125 patients received ABV every 2 weeks with a planned total of 6 cycles. Patients completed a 30-item AIDS-related HRQL questionnaire before beginning treatment (baseline), every 2 weeks while on treatment, and about 21 days after the end of treatment. Twenty-two items, involving nine domains, were analyzable. While on treatment, PLD-treated patients with partial clinical responses achieved statistically significant greater improvement (compared to baseline) in general health than did ABV-treated patients with partial clinical responses (ρ = 0.008). By the end of treatment, the overall group of patients receiving PLD showed statistically significant greater improvement in pain and energy/fatigue than did the group receiving ABV (ρ = 0.01–0.002). In addition, duration of clinically significant improvement in global QL was longer in the PLD arm.

• Acquired immunodeficiency syndrome (AIDS)
• Bleomycin
• Doxorubicin
• Health-related quality of life
• Kaposi's sarcoma
• Pegylated-liposomal doxorubicin
• Vincristine